Caris Life Sciences (CAI) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Caris Life Sciences (NASDAQ: CAI):

• 10/27/2026 – Caris Life Sciences had its price target raised by BTIG Research from $33.00 to $38.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Caris Life Sciences had its price target raised by Canaccord Genuity Group from $22.00 to $30.00. They now have a “hold” rating on the stock.
• 10/14/2026 – Caris Life Sciences had its price target raised by JPMorgan Chase & Co. from $25.00 to $35.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – Caris Life Sciences had its price target raised by TD Cowen from $30.00 to $36.00. They now have a “buy” rating on the stock.
• 10/2/2026 – Caris Life Sciences was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/16/2026 – Caris Life Sciences was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 9/9/2026 – Caris Life Sciences is now covered by UBS Group. They set a “neutral” rating and a $28.00 price target on the stock.
• 9/9/2026 – Caris Life Sciences is now covered by UBS Group. They set a “hold” rating and a $28.00 price target on the stock.

Caris Life Sciences Stock Performance

Shares of CAI stock opened at $32.10 on Tuesday. The firm has a 50 day moving average of $29.28 and a 200-day moving average of $21.68. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $36.50. The company has a market cap of $9.07 billion, a price-to-earnings ratio of 89.17 and a beta of 0.86. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66.

Insider Activity at Caris Life Sciences

In other news, President David Spetzler sold 478,000 shares of Caris Life Sciences stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the completion of the sale, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. This trade represents a 31.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian J. Brille sold 400,000 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the transaction, the insider directly owned 230,303 shares in the company, valued at approximately $6,985,089.99. This represents a 63.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,004,712 shares of company stock valued at $27,205,419 over the last 90 days. Insiders own 50.00% of the company’s stock.

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.